AQUESTIVE THERAPEUTICS INC
NASDAQ: AQST (Aquestive Therapeutics, Inc.)
最近更新时间: 昨天, 1:15AM3.46
-0.25 (-6.61%)
新闻情绪
-
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
06 Nov, 1:05PM
-
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03 Nov, 3:01PM
AIStockmoo 评分
| 价值 30% | -1.7 |
| 盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -4.1 |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价接近均线。下跌日成交量较大。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.1 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 1.2 |
| 内部人士近期净买入。股价低于内部人士的买入价。 参考 | |
| 机构在最新13F申报中净+3.33%的股份:95家增持,78家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+15.1%,回补天数13.2天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现优于大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利有升有降。近年曾亏损。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 股价接近支撑位。支撑与阻力水平趋降。 参考 | |
| 最终评分 | -1.70 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Aquestive Therapeutics, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| AQST | 435 M | - | - | - | -1.7 |
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| TLRY | 279 M | - | - | 0.200 | -2.2 |
|
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 10.78% |
| 机构持股比例 | 61.11% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bratton Capital Management, L.P. | 30 Sep 2026 | 9,810,958 |
| Rosalind Advisors, Inc. | 30 Sep 2026 | 2,000,000 |
| Blue Owl Capital Holdings Lp | 30 Sep 2026 | 1,390,632 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| DALY RICHARD J | 3.52 | - | 28,025 | 98,648 |
| DAVIS MATTHEW W. | - | 3.55 | -12,500 | -44,360 |
| 累积净数量 | 15,525 | |||
| 累积净值 ($) | 54,288 | |||
| 累积平均购买 ($) | 3.52 | |||
| 累积平均卖出 ($) | 3.55 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| DAVIS MATTHEW W. | 职员 | 12 Nov 2026 | 卖 (-) | 7,197 | 3.57 | 25,693 |
| DAVIS MATTHEW W. | 职员 | 10 Nov 2026 | 处理 (-) | 5,303 | 3.52 | 18,667 |
| DALY RICHARD J | 董事 | 10 Nov 2026 | 买 (+) | 28,025 | 3.52 | 98,648 |
机构
机构持股比例: 65.06%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 95 | 11,250,763 |
| 减持 | 78 | 7,172,973 |
| 新建仓 | 26 | 2,010,558 |
| 清仓 | 20 | 1,892,405 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 29,318,686 | 13.2 |
| 15 Oct 2026 | 27,597,742 | 13.9 |
| 30 Sep 2026 | 28,748,212 | 13.1 |
| 15 Sep 2026 | 27,161,738 | 11.8 |
| 31 Aug 2026 | 25,478,782 | 7.2 |
| 14 Aug 2026 | 20,951,747 | 5.2 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will… |
| 16 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Aquestive Therapeutics (NASDAQ:AQST) is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference. The company’s lead product candidate, An… |
| 09 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will… |
| 06 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
Aquestive Therapeutics Inc (AQST) navigates quarterly revenue fluctuations while advancing Anifilm toward a March 2027 FDA decision and securing a $10 million upfront licensing deal for Libervant. |
| 05 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster… |
| 04 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aquestive Therapeutics, Inc.'s Q3 2026 earnings call… |
| 04 Nov 2026 | Yahoo Finance |
Aquestive (AQST) Q3 2026 Earnings Call Transcript
Anaphylm's March 2027 FDA date anchors a launch push backed by new funding. |
| 04 Nov 2026 | Yahoo Finance |
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
Aquestive Therapeutics (NASDAQ:AQST) said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is preparing for a potential U.S. launch next year if the product receives Food and Drug Administratio… |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.00% and -31.51%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics: Q3 Earnings Snapshot
(AP) — Aquestive Therapeutics Inc. (AQST) on Tuesday reported a loss of $16… |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approvedCommercial preparations remain on track to support a potential U.S. launch of Anaphylm… |
| 27 Oct 2026 | Yahoo Finance |
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that… |
| 15 Oct 2026 | Yahoo Finance |
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive… |
| 14 Oct 2026 | Yahoo Finance |
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient market research demonstrated strong preference for buccal film, with 71% of… |
| 29 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc.… |
| 17 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026… |
| 07 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
On August 11, Aquestive Therapeutics (NASDAQ:AQST) reported second-quarter 2026 results and said it remains on track to resubmit its Anaphylm epinephrine film to the FDA in the third quarter of 2026. That single sentence carries the whole story here. A company living and dying by one product… |
| 01 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the… |
| 显示更多 | ||
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合